Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance | |
Zhang,Tao1; Qu,Rong1; Chan,Shingpan2; Lai,Mengzhen1,3; Tong,Linjiang1; Feng,Fang1; Chen,Hongyu4; Song,Tingting4; Song,Peiran1; Bai,Gang1,5,6 | |
刊名 | Molecular Cancer |
2021-08-17 | |
卷号 | 20期号:1 |
DOI | 10.1186/s12943-021-01391-x |
通讯作者 | Ding,Ke(dingke@jnu.edu.cn) ; Ding,Jian(jding@simm.ac.cn) ; Xie,Hua(hxie@simm.ac.cn) |
语种 | 英语 |
出版者 | BioMed Central |
WOS记录号 | BMC:10.1186/S12943-021-01391-X |
内容类型 | 期刊论文 |
源URL | [http://119.78.100.183/handle/2S10ELR8/297582] |
专题 | 中国科学院上海药物研究所 |
通讯作者 | Ding,Ke; Ding,Jian; Xie,Hua |
作者单位 | 1.Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research 2.Jinan University; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy 3.Fudan University; School of Pharmacy 4.Jiangsu Aosaikang Pharmaceutical Co.Ltd (ASK pharm) 5.University of Chinese Academy of Sciences 6.ShanghaiTech University; School of Life Science and Technology |
推荐引用方式 GB/T 7714 | Zhang,Tao,Qu,Rong,Chan,Shingpan,et al. Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance[J]. Molecular Cancer,2021,20(1). |
APA | Zhang,Tao.,Qu,Rong.,Chan,Shingpan.,Lai,Mengzhen.,Tong,Linjiang.,...&Xie,Hua.(2021).Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.Molecular Cancer,20(1). |
MLA | Zhang,Tao,et al."Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance".Molecular Cancer 20.1(2021). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论